Trial Management Group
|Two trials were recently activated.
SC.22 -- A Phase I Study to Determine the Dose of Methadone as a First-Line Agent in the Treatment of Chronic Neuropathic Cancer Pain -- was centrally activated 17 April 2009.
We anticipate the participation of eight centres (CAHC, CAKK, CAMP, CARM, CATW, CAVA, CAVF, CAVK).
Eligible patients will be taking the equivalent of 75 mg of oral morphine or less, on average, for the three full days prior to registration. If the average oral morphine equivalent dose is 45 mg or less, the patient is included in Arm A. If the average oral morphine equivalent dose is more than 45 mg but less than or equal to 75 mg, the patient is included in Arm B. The patient is then assigned to the appropriate Dose Level within the Arm. The maximum number of patients that can be enrolled on the study is 60 (i.e., 10 patients in each of the three dose levels on the two arms). The total maximum duration of therapy with methadone tablets is 35 days.
ALC.2 -- A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND # 101261) or Placebo in Newly-Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)-- was centrally activated 21 April 2009.